header logo image


Page 36«..1020..35363738..5060..»

Archive for the ‘Arthritis’ Category

Understanding acute and chronic inflammation – Harvard Health

Saturday, March 21st, 2020

The right kind of inflammation is essential to your body's healing system. But chronic inflammation can be a problem.

Published: April, 2020

The saying "too much of a good thing" applies to much of life, but especially to inflammation.

"People think inflammation needs to be stomped out at all times, but it plays an essential role in healing and injury repair to keep your body safe and healthy," says Dr. Robert H. Shmerling, medical editor of Understanding Inflammation from Harvard Health Publishing and an associate professor of medicine at Harvard Medical School. "Some inflammation is good. Too much is often bad. The goal is to recognize when inflammation is simply doing its job, and when it can potentially cause problems."

Signs of inflammation are like a car's dashboard engine light. It tells you that something is wrong. But your response is not to take out the bulb, because that's not the problem. Instead, you look at what caused the light to turn on. "It's the same with inflammation," says Dr. Shmerling. "It's telling you that something bigger is going on that requires attention."

There are two types of inflammation: acute and chronic. People are most familiar with acute inflammation. This is the redness, warmth, swelling, and pain around tissues and joints that occurs in response to an injury, like when you cut yourself. When the body is injured, your immune system releases white blood cells to surround and protect the area.

"Acute inflammation is how your body fights infections and helps speed up the healing process," says Dr. Shmerling. "In this way, inflammation is good because it protects the body." This process works the same if you have a virus like a cold or the flu.

In contrast, when inflammation gets turned up too high and lingers for a long time, and the immune system continues to pump out white blood cells and chemical messengers that prolong the process, that's known as chronic inflammation. "From the body's perspective, it's under consistent attack, so the immune system keeps fighting indefinitely," says Dr. Shmerling.

When this happens, white blood cells may end up attacking nearby healthy tissues and organs. For example, if you are overweight and have more visceral fat cells the deep type of fat that surrounds your organs the immune system may see those cells as a threat and attack them with white blood cells. The longer you are overweight, the longer your body can remain in a state of inflammation.

Research has shown that chronic inflammation is associated with heart disease, diabetes, cancer, arthritis, and bowel diseases like Crohn's disease and ulcerative colitis.

Yet, because chronic inflammation can continue for a long time, it's not easy to know its exact impact. "It's a chicken-and-egg scenario," says Dr. Shmerling. "Does chronic inflammation increase the risk of these ailments, or is it a byproduct? It is not always clear."

Here are some other steps you can take to prevent and reduce chronic inflammation:

Most of the time, you don't need to worry too much about acute inflammation, says Dr. Shmerling. You can take an over-the-counter pain reliever to help relieve symptoms, or apply cold compresses to reduce swelling. "Otherwise, it is usually best to let the inflammation do its work to help with healing," says Dr. Shmerling.

Of course, the cause of acute inflammation may need treatment. For example, a bacterial infection may require antibiotics, so if you have a fever or significant symptoms such as severe pain or shortness of breath see your doctor.

Chronic inflammation is trickier to deal with. The problem is that chronic inflammation is often "invisible," since it does not show telltale physical signs the way acute inflammation does.

So how can you prevent or reduce inflammation you cannot necessarily see or feel?

The only way to detect chronic inflammation is to have an evaluation by your doctor. He or she will review your symptoms, perform a physical exam, and perhaps check your blood for signs of inflammation. (See "A test for inflammation.")

Otherwise, the best approach is to prevent conditions related to chronic inflammation. "It goes back to the basics: maintaining a healthy weight, choosing a good diet, getting plenty of sleep, and exercising regularly," says Dr. Shmerling.

How do you know if you have chronic inflammation? A blood test measures a protein produced by the liver, C-reactive protein (CRP), which rises in response to inflammation. A CRP level between 1 and 3 milligrams per liter of blood often signals a low, yet chronic, level of inflammation. The erythrocyte sedimentation rate is another blood test for inflammation. It is used for people with inflammatory conditions, like rheumatoid arthritis.

Diet and exercise have an especially strong impact on managing chronic inflammation since they both also can help control weight and improve sleep.

The evidence is not clear that a specific type of diet can prevent chronic inflammation. However, certain foods are associated with either promoting or inhibiting the inflammatory response. These foods also are linked to a lower risk of problems related to chronic inflammation, such as heart disease, weight gain, and cancer.

For instance, cut back or eliminate foods high in simple sugars like soda, fruit juices with added sugars, sports drinks, processed meat, and refined carbs like white bread and pasta. "These foods can spike blood sugar levels, which can lead to overeating and weight gain," says Dr. Shmerling.

Also, eat more foods high in the antioxidants known as polyphenols, which can lower inflammation. Examples include all types of berries, cherries, plums, red grapes, onions, turmeric, green tea, and dark green leafy vegetables like spinach and kale.

Regular exercise can help protect against conditions linked with chronic inflammation, especially heart disease and obesity. A 2017 study in Brain, Behavior, and Immunity found that just 20 minutes of moderate-intensity exercise (in this case, walking on a treadmill) can have an anti-inflammatory effect.

Image: Mingirov/Getty Images

Disclaimer:As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

The rest is here:
Understanding acute and chronic inflammation - Harvard Health

Read More...

New Research Among People Living With Rheumatoid Arthritis Reveals Key Determinants Of Patient Satisfaction With Doctors – Monterey County Weekly

Friday, March 20th, 2020

SAN FRANCISCO, March 20, 2020 /PRNewswire/ --MyHealthTeams, creator of the largest and fastest-growing social networks for people facing chronic health conditions, today unveiled new research conducted among registered members of myRAteam, the social network for people living with rheumatoid arthritis (RA). Key findings spanned topics including patient satisfaction with their doctors, the impact RA has on quality of life, and common symptoms and flare-up triggers.

"Joint pain is just the tip of the iceberg for those living with rheumatoid arthritis. You've got to treat the whole person, not just their obvious symptoms," said Eric Peacock, cofounder and CEO of MyHealthTeams. "RA patients in this research made it clear that the best rheumatologists are those who take the time to truly understand the full range of symptoms and the quality of life impact people with RA are experiencing. The gap between patients satisfied and dissatisfied with their doctors was stark."

Patient Satisfaction: Determined by listening/understanding, time spent, and breadth of discussionThere is a high correlation between treatment satisfaction and doctor satisfaction, so if treatment isn't working to control a patient's RA, it's unlikely she will be satisfied with her doctor. But treatment effectiveness isn't the only driver. The study revealed a significant experience gap between those who are satisfied or not with their doctors. Among the 57% of RA patients who report overall satisfaction with their doctors: 87% feel their doctor listens to them and understands their needs; 81% believe their doctor spends enough time with them; 74% report their doctor addresses symptoms such as pain, depression and anxiety; 65% discuss treatment side effects with their doctor; and 52% say their doctor has worked with them to develop a long-term plan. Among the 43% of RA patients who report overall dissatisfaction with their doctors, these numbers drop to 24%, 26%, 20%, 29% and 12% respectively.

Impact on Quality of Life: Daily challenges and emotional impacts take toll at home, work and beyond RA, a chronic inflammatory condition in which the body's immune system attacks its own tissue, including joints, has wide-ranging impact on quality of life.

Further, the emotional toll of RA is significant.

Symptoms and Triggers: Aggravated by environmental factors, disease causes symptoms well beyond joint pain and stiffnessBeyond the joint pain and stiffness experienced by nearly everyone surveyed, myRAteam members report a broad spectrum of symptoms, including:

The top reported triggers for flare-ups of RA symptoms are stress (79%) and cold weather (73%).

This research was conducted among registered members of myRAteam. 374 individuals responded to the online survey. Full survey findings are available at https://www.myrateam.com/resources/the-results-are-in-people-living-with-rheumatoid-arthritis-are-more-satisfied-with-their-doctors-when-they-feel-heard-and-understood

About MyHealthTeamsMyHealthTeamsbelieves that if you are diagnosed with a chronic condition, it should be easy to find and connect with others like you. MyHealthTeams creates social networks for people living with a chronic health condition. Millions of people have joined one of the company's 35 highly engaged communities focusing on the following conditions: Crohn's and colitis, multiple sclerosis, lupus, fibromyalgia, pulmonary hypertension, spondylitis, eczema, myeloma, hyperhidrosis, vitiligo, rheumatoid arthritis, psoriasis, leukemia, lymphoma, irritable bowel syndrome, Parkinson's, Alzheimer's, epilepsy, hemophilia, hidradenitis suppurative, depression, heart disease, type 2 diabetes, osteoporosis, COPD, chronic pain, migraines, food allergies, obesity, HIV, PCOS, endometriosis, breast cancer and autism. MyHealthTeams' social networks are available in 13 countries.

Read this article:
New Research Among People Living With Rheumatoid Arthritis Reveals Key Determinants Of Patient Satisfaction With Doctors - Monterey County Weekly

Read More...

Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial – DocWire…

Friday, March 20th, 2020

INTRODUCTION:

The objective of this study was to assess efficacy and safety of repository corticotropin injection (RCI) in subjects with activerheumatoid arthritis(RA) despite treatment with a corticosteroid and one or two disease-modifying antirheumatic drugs (DMARDs).

All subjects received open-label RCI (80 U) twice weekly for 12weeks (part 1); only those with low disease activity [LDA; i.e., Disease Activity Score 28 joint count and erythrocyte sedimentation rate (DAS28-ESR)<3.2] were randomly assigned to receive either RCI (80 U) or placebo twice weekly during the 12-week double-blind period (part 2). The primary efficacy endpoint was the proportion of subjects who achieved LDA at week 12. Secondary efficacy endpoints included proportions of subjects who maintained LDA during weeks 12 through 24 and achieved Clinical Disease Activity Index (CDAI)10 at weeks 12 and 24. Safety was assessed via adverse event reports.

Of the 259 enrolled subjects, 235 completed part 1; 154 subjects (n=77 each for RCI and placebo) entered part 2, and 127 (RCI, n=71; placebo, n=56) completed. At week 12, 163 subjects (62.9%) achieved LDA and 169 (65.3%) achieved CDAI10 (both p<0.0001). At week 24, 47 (61.0%) RCI-treated and 32 (42.1%) placebo-treated subjects maintained LDA (p=0.019); 66 (85.7%) RCI-treated and 50 (65.8%) placebo-treated subjects maintained CDAI10 (p=0.004). No unexpected safety signals were observed.

RCI was effective and generally safe in patients with active RA despite corticosteroid/DMARD therapy. By week 12,>60% of patients achieved LDA, which was maintained with 12 additional weeks of treatment. Most patients who achieved LDA maintained it for 3months after RCI discontinuation.

Clinicaltrials.gov identifierNCT02919761.

See more here:
Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial - DocWire...

Read More...

Relationship between disease activity of rheumatoid arthritis and development of locomotive syndrome: A five-year longitudinal cohort study – DocWire…

Friday, March 20th, 2020

OBJECTIVE:

This study aimed to longitudinally evaluate the association betweenrheumatoid arthritis(RA) and locomotive syndrome (LS) in RA patients using the 25-question Geriatric Locomotive Function Scale (GLFS-25).

Subjects were 58 RA patients (female, 48 (82.8%); mean age, 60.910.9 years) who had GLFS-25 scores available for five consecutive years and who did not have LS at baseline (i.e., GLFS-25<16 points). Associations between DAS28-CRP and the development of LS were determined using linear regression analysis and receiver operating characteristic (ROC) curve analysis.

Subjects were divided into the LS group (n=15, GLFS-2516 points) and Non-LS group (n=43, GLFS-25<16 points) based on GLFS-25 scores at the 5th year of the study period. In the LS group, DAS28-CRP worsened every year. The linear regression model adjusted for age and sex revealed that GLFS-25 increased by 3.80 (95% confidence interval: 1.81-5.79) each time DAS28-CRP increased by 1 (p<0.001). Among patients in remission (DAS28-CRP <2.3), 13.5% had LS. ROC curve analysis yielded a five-year mean DAS28-CRP of 1.99 (sensitivity, 86.7%; specificity, 62.8%) as the cut-off point for the development of LS.

Tight control of RA disease activity for deeper remission may be needed to prevent the development of LS.

Read the rest here:
Relationship between disease activity of rheumatoid arthritis and development of locomotive syndrome: A five-year longitudinal cohort study - DocWire...

Read More...

Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices -…

Friday, March 20th, 2020

OBJECTIVE:

The aim of this study was to evaluate the discriminant capability of the Patient Acceptable Symptom State (PASS) according to disease activity, remission/low disease activity indices and quality of life indices in patients withpsoriatic arthritis(PsA).

Consecutive patients with PsA were enrolled in this cross-sectional study. At each visit, the patients underwent a complete physical examination and their clinical/laboratory data were collected. Disease activity was assessed using the Disease Activity Score forPsoriatic Arthritis(DAPSA) and remission/low disease activity using the DAPSA minimal disease activity (MDA) and very low disease activity (VLDA) criteria. ThePsoriatic ArthritisImpact of Disease (PsAID) and the Health Assessment Questionnaire-Disability Index scores were also collected. Finally, PASS was assessed by asking all patients to answer yes or no to a single question.

Patients who answered yes to PASS showed a significantly better overall mean DAPSA score than those who were not in PASS. Furthermore, patients in PASS showed a significantly lower level of systemic inflammation, lower Leeds Enthesitis Index score, a significantly lower impact of disease (PsAID), lower pain and better function than patients who answered no to PASS. A moderate to good agreement was found between PASS, MDA, DAPSA low disease activity and PsAID score 4. Good sensitivity and specificity were found with PASS with respect to DAPSA low disease activity, and although PASS is sensitive in the identification of patients with MDA, DAPSA remission and VLDA it lacks of specificity.

This study showed that PASS might be used as an alternative to determine disease activity in patients with PsA in real clinical practice, mainly in patients with low disease activity according to DAPSA criteria.

Read this article:
Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices -...

Read More...

FDA Approves OTC Combination of Ibuprofen and Acetaminophen for Minor Arthritis Pain – Rheumatology Advisor

Friday, March 20th, 2020

Home Topics Pain Management

The FDA has approved Advil Dual Action with Acetaminophen (GlaxoSmithKline), the first over-the-counter (OTC) fixed-dose combination therapy containing ibuprofen and acetaminophen for the temporary relief of minor aches and pains due to headache, backache, muscular aches, toothache, menstrual cramps, and minor pain of arthritis.

Each caplet contains 125mg of Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) and 250mg of acetaminophen and is indicated for adults and children 12 years of age and older. The approval was based on study data that showed use of the fixed-dose combination therapy was associated with superior pain relief compared with the individual components taken alone.

Advil Dual Action with Acetaminophen is expected to be available nationwide sometime during 2020.

GlaxoSmithKline recently received FDA approval for another OTC pain reliever, Voltaren Arthritis Pain (diclofenac topical gel), for the temporary relief of arthritis pain in the hand, wrist, elbow, foot, ankle or knee in adults 18 years old. The OTC formulation is the same as the prescription strength (10mg of diclofenac sodium per gram or 1%). It is expected to be available in spring 2020.

For more information visit gsk.com.

This article originally appeared on MPR

Please login or register first to view this content.

LoginRegister

Next post in Pain ManagementClose

Go here to see the original:
FDA Approves OTC Combination of Ibuprofen and Acetaminophen for Minor Arthritis Pain - Rheumatology Advisor

Read More...

Rheumatoid Arthritis Treatment Market Share, Size, Future Demand, Global Research, Top Leading Player, Emerging Trends and Forecast to 2029 – Daily…

Friday, March 20th, 2020

The Rheumatoid Arthritis Treatment Market study offers an in-depth analysis of the current market trends influencing this business vertical. The study also includes market valuation, market size, revenue forecasts, geographical spectrum and SWOT Analysis of the industry. In addition, the report depicts key challenges and growth opportunities faced by the industry bigwigs, in consort with their product offerings and business strategies.

A collective analysis of Rheumatoid Arthritis Treatment Market offering an exhaustive study based on current trends influencing this vertical across various geographies has been provided in the report. Also, this research study estimates this space to accrue considerable income during the projected period, with the help of a plethora of driving forces that will boost the industry trends during the forecast duration. Snippets of these influences, in tandem with countless other dynamics relating to the Rheumatoid Arthritis Treatment Market, like the risks that are predominant across this industry along with the growth prospects existing in Rheumatoid Arthritis Treatment Market, have also been charted out in the report.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.xploremr.com/connectus/sample/2263

The report covers exhaustive analysis on:

Regional analysis includes

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! https://www.xploremr.com/connectus/check-discount/2263

The report provides extensive data concerning the market share that each one of these companies presently gather throughout this business, followed by the market share that they are anticipated to acquire by the end of the predicted timeframe. Also, the report expounds on details relating to the goods manufactured by these firms, that would help new industry participants and major stakeholders work on their competition and portfolio strategies. In addition, their policymaking process is likely to get easier since the Rheumatoid Arthritis Treatment Market report also enumerates an idea of the trends in product prices and the revenue margins of all the major companies partaking in the industry share.

Queries that the Rheumatoid Arthritis Treatment Market report answers in respect of the regional landscape of the business domain:

Get Full Report Access athttps://www.xploremr.com/cart/2263/SL

Significant takeaways from the study:

The Rheumatoid Arthritis Treatment Market report hosts excess deliverables that may be highly advantageous. Say for instance, the report emphasizes information regarding market competition trends extremely essential data subject to contender intelligence and the current industry drifts that would enable shareholders to compete and take advantage of the biggest growth opportunities in the Rheumatoid Arthritis Treatment Market.

Another vital takeaway from the report can be accredited to the industry concentration rate that could help stakeholders to speculate on the existing sales dominance and the probable trends of the forthcoming years.

Additional deliverables mentioned in the report include details pertaining to the sales channels deployed by prominent sellers in order to retail their status in the industry, including direct and indirect marketing.

About Us

XploreMR is one of the worlds leading resellers of high-quality market research reports. We feature in-depth reports from some of the worlds most reputed market research companies and international organizations. We serve across a broad spectrum from Fortune 500 to small and medium businesses. Our clients trust us for our unwavering focus onquality and affordability. We believe high price should not be a bottleneck for organizations looking to gain access to quality information.

Contact us:

XploreMR111 North Market Street, Suite 300,San Jose, CA 95113, United StatesPh.No: +16692840108E-mail id-[emailprotected]Web-https://www.xploremr.com

Read the original:
Rheumatoid Arthritis Treatment Market Share, Size, Future Demand, Global Research, Top Leading Player, Emerging Trends and Forecast to 2029 - Daily...

Read More...

Rheumatoid Arthritis Diagnosis Tests Market expected to Witness a Sustainable Growth over 2017 2025 – Feed Road

Friday, March 20th, 2020

Rheumatoid Arthritis Diagnosis Tests Market size will reach xx million US$ by 2029, from xx million US$ in 2018, at a CAGR of xx% during the forecast period. In this study, 2018 has been considered as the base year and2017 2025 as the forecast period to estimate the market size for Rheumatoid Arthritis Diagnosis Tests.

This industry study presents the Rheumatoid Arthritis Diagnosis Tests Market size, historical breakdown data 2014-2019 and forecast 2017 2025. The Private Plane production, revenue and market share by manufacturers, key regions and type; The consumption of Rheumatoid Arthritis Diagnosis Tests Market in volume terms are also provided for major countries (or regions), and for each application and product at the global level.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.xploremr.com/connectus/sample/336

Rheumatoid Arthritis Diagnosis Tests Market report coverage:

The Rheumatoid Arthritis Diagnosis Tests Market report covers extensive analysis of the market scope, structure, potential, fluctuations, and financial impacts. The report also enfolds the precise evaluation of market size, share, product & sales volume, revenue, and growth rate. It also includes authentic and trustworthy estimations considering these terms.

The Rheumatoid Arthritis Diagnosis Tests Market has been reporting substantial growth rates with considerable CAGR for the last couple of decades. According to the report, the market is expected to grow more vigorously during the forecast period and it can also influence the global economic structure with a higher revenue share. The market also holds the potential to impact its peers and parent market as the growth rate of the market is being accelerated by increasing disposable incomes, growing product demand, changing consumption technologies, innovative products, and raw material affluence.

The study objectives are Rheumatoid Arthritis Diagnosis TestsMarket Report:

In this study, the years considered to estimate the market size of Rheumatoid Arthritis Diagnosis TestsMarket:

History Year: 2014 2018

Base Year: 2018

Estimated Year: 2019

Forecast Year:2017 2025

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Rheumatoid Arthritis Diagnosis Tests Market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! https://www.xploremr.com/connectus/check-discount/336

The report covers exhaustive analysis on:

Regional analysis includes

Get Full Report Access athttps://www.xploremr.com/cart/336/SL

Benefits of Purchasing from XMR:

About Us

XploreMR is one of the worlds leading resellers of high-quality market research reports. We feature in-depth reports from some of the worlds most reputed market research companies and international organizations. We serve across a broad spectrum from Fortune 500 to small and medium businesses. Our clients trust us for our unwavering focus onquality and affordability. We believe high price should not be a bottleneck for organizations looking to gain access to quality information.

Contact us:

XploreMR111 North Market Street, Suite 300,San Jose, CA 95113, United StatesPh.No: +16692840108E-mail id-[emailprotected]Web-https://www.xploremr.com

Read the original here:
Rheumatoid Arthritis Diagnosis Tests Market expected to Witness a Sustainable Growth over 2017 2025 - Feed Road

Read More...

Fight Inflammation With Tart Cherry Juice – Newsmax

Friday, March 20th, 2020

Tart cherry juice is the latest health rage and for good reason. The cancer-fighting beverage may also protect against heart disease, reduce arthritis symptoms, and help you sleep more soundly.

"Tart cherries are loaded with important nutrients, but you'd have to eat an entire bag of them to obtain all the benefits you get by sipping the juice," says Michele Turcotte, M.S., R.D., a dietitian and nutritionist in Lake Geneva, Wisconsin. "Its juice contains many antioxidants and anti-inflammatory agents, which can help alleviate a variety of ailments like asthma symptoms and pain."

Turcotte explains that tart cherries, like all red fruits and vegetables, are rich in anthocyanins, a particularly potent antioxidant phytochemical.

"Anthocyanins encourage healthy circulation, ensure proper nerve function, and offer cancer-fighting properties," says the expert. A research study published in the Journal of Nutrition says that tart cherry juice provides older adults great protection against the development of heart disease, cancer and age-related cognitive decline.

Here are more health benefits:

* Heart disease and diabetes. The quercetin found in tart cherry juice is another powerful antioxidant that helps prevent free radical damage caused by low-density lipoprotein or LDL, according to a 2013 study. When LDL cholesterol is oxidized, its more likely to stick to arterial walls, forming plaque that contributes to heart attack and stroke.

Another study published in the International Journal of Preventative Medicine noted that intake of high levels of quercetin were associated with reduced risk of type 2 diabetes.

* Insomnia. Drinking an 8-ounce glass of tart cherry juice in the morning and the evening may be a better and safer way to treat insomnia than taking drugs, according to researchers at Louisiana State University. Tart cherries are a natural source of melatonin, a hormone that helps regulate the sleep-wake cycle.

* Sports recovery and muscle damage. Marathon runners who consumed 8 ounces of tart cherry juice twice daily for five days prior to a marathon, on the day of the marathon, and then for two days afterward reported less muscle damage, soreness, inflammation, and protein breakdown than runners who consumed a placebo, according to research published in the Scandinavian Journal of Medicine and Science in Sports.

* Arthritis and gout. Tart cherry juice may reduce arthritis symptoms such as joint pain and inflammation, according to several studies. A 2012 study revealed that folks with osteoarthritis who drank tart cherry juice for 21 days had reduced symptoms of pain.

* Brain health. Since degenerative brain disorders like Parkinson's and Alzheimer's are thought to be causeed, in part, by oxidative stress, drinking tart cherry juice may have protective effects on brain cells. In fact, in one study, older adults with mild-to-moderate cognitive decline consumed 6 ounces of tart cherry juice daily or a placebo for 12 weeks. The adults in the tart cherry juice group experienced improvement in verbal fluency, short term memory, and long-term memory, whereas the placebo group experienced no improvement.

2020 NewsmaxHealth. All rights reserved.

Read the rest here:
Fight Inflammation With Tart Cherry Juice - Newsmax

Read More...

Regeneron to treat coronavirus patients this week in trial using its rheumatoid arthritis drug – CNBC

Thursday, March 19th, 2020

Regeneron Pharmaceuticals this week initiated test trials of an arthritis drug as a potential remedy for the worst symptoms of COVID-19, the disease caused by the novel coronavirus.

The biotech giant announced Monday it launched a clinical program using Kevzara, a commercial medicine that treats active rheumatoid arthritis, and recruiting hospitalized patients experiencing severe symptoms of the respiratory illness.

"We did something that's never been done in record time," launching a study in New York state "where we're going to already be treating patients with this," Regeneron Chief Scientific Officer Dr. George Yancopoulos told CNBC'sJim Crameron Tuesday.

The Regeneron co-founder and president hopes within a few weeks that results will support findings from China, where health officials tried a variety of medicines to combat the disease as the virus spread quickly. Kevzara is an antibody that could help prevent the lungs from triggering an overactive inflammatory response, Regeneron said.

"The one thing everybody got excited about is something that blocked inflammation. This was done in an uncontrolled way, not a randomized controlled study," Yancopoulos said in the "Mad Money" interview.

Regeneron is working with the U.S. Food and Drug Administration and the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority to get the trials underway, he added.

If successful, it could be used as an immediate remedy for patients in critical condition.

"[W]e're going to be hopefully seeing within a few weeks whether this really replicates and confirms the positive suggestions that are coming out of China,"Yancopoulos said. "If they are, it means for the most seriously ill patients we may have something that keeps them from having to go on ventilators or be able to maybe take off ventilators."

Regeneron is working on the clinical program with Sanofi, the French drugmaker leading the study abroad. The biotech companies co-developed Kevzara, which received FDA approval in 2017.

The U.S. trial will launch in medical centers in New York, the state hardest hit by the coronavirus pandemic, and is expected to enroll as many as 400 patients in more than a dozen states. The second phase of the program will study long-term outcomes, according to a press release.

"This could in a very short time give hope to the most critical people,"Yancopoulos said.

Outside of the Kevzara trial, Regeneron announced Tuesday it plans to begin testing a coronavirus antibody treatment on humans sooner than once expected. The company moved its timeline up for human testing from late summer to early summer.

There are more than 7,300 confirmed cases in the United States as of Wednesday afternoon, according to data compiled by Johns Hopkins University.

Read the original post:
Regeneron to treat coronavirus patients this week in trial using its rheumatoid arthritis drug - CNBC

Read More...

Here are some of the existing drugs that may be repurposed to treat coronavirus – NBCNews.com

Thursday, March 19th, 2020

Pharmaceutical companies and research facilities are working to find new, successful treatments for those infected with coronavirus. But clinical trials and FDA approval can take time, so while new drugs are being developed, companies are seeing if older drugs can be repurposed.

Heres a list of some of the options being explored and why they might be useful in blunting the effects of coronavirus.

Doctors in China have used an anti-inflammation drug to curb the effects of the coronavirus on critical patients, and now the maker of the drug says it is talking to the Food and Drug Administration about clinical trials.

Tocilizumab, sold under the name Actemra and made by the Swiss pharmaceutical firm Roche, is a prescription medicine used to treat adults with moderate to severe active rheumatoid arthritis, as well as certain types of juvenile arthritis.

Chinese doctors have used Tocilizumab to prevent an overreaction of the immune system that has led to organ failure and death in coronavirus patients. An initial clinical trial in China used Actemra in 20 severe COVID-19 cases. Nineteen of the patients were discharged from the hospital within two weeks and one got better, according to Chinas National Health Commission. The drug has now been approved for use in China, but has not yet been approved in the United States.

Let our news meet your inbox. The news and stories that matters, delivered weekday mornings.

Karsten Kleine, a spokesperson for Roche, told NBC News that the drug company is in active discussions with the FDA, as well as government bodies and institutions around the world, to initiate clinical trials that evaluate the safety and efficacy of Actemra (tocilizumab) for the treatment of severely ill COVID-19 patients.

Roche is not alone in looking into rheumatoid arthritis drugs as a potential treatment. Sanofi and Regeneron are launching a clinical trial in New York to see if their rheumatoid arthritis drug Kevzara is effective.

AbbVie, the creator of HIV drugs Kaletra/Aluvia, is collaborating with health authorities to determine the efficacy of using its HIV drugs to treat COVID-19. The company is working with the FDA, CDC, and European agencies to set up clinical trials of the drug.

At this time, AbbVie told NBC News it cannot confirm Chinese media reports that the drug has been successful in treatment as it does not have access to Chinese clinical information. It is monitoring its current supply to make sure current HIV patients being treated by the drug will not be affected by an increase in demand.

Sanofi is assessing the risk and benefit of its malaria drug hydroxychloroquine for the management of coronavirus. According to the company, some health authorities are allowing the temporary use of chloroquine for the management of COVID-19, but there is insufficient data to draw any conclusions over its efficacy. Any use of the drug in this context is considered off-label use.

Based on encouraging preliminary findings from a study in France, Sanofi is looking at ways to collaborate and partner with health authorities investigating the use of hydroxychloroquine for the management of coronavirus.

Remdesivir is a broad spectrum anti-viral medication developed by Gilead Sciences as a treatment for Ebola and also showed success in treatment of monkeys infected with MERs, a different type of coronavirus. It is now being tested as a potential COVID-19 treatment.

Remdesivir is in clinical trials in China and the U.S. at the University of Nebraska Medical Center. There are 20 locations involved in the trial and seven are recruiting for participants, including Emory Vaccine Center in Atlanta and The University of Washington Virology Research Clinic. All participants must have laboratory-confirmed SARS-CoV-2 infection with symptoms showing evidence of lung involvement, rattling sounds when breathing with a need for supplemental oxygen or abnormal chest X-rays, or illness requiring mechanical ventilation.

The first participant is an American who was on the Diamond Princess cruise ship that docked in Yokohama, Japan.

Those with a confirmed infection who have mild symptoms or no apparent symptoms at all cannot participate in the study.

Emily Siegel is an associate producer with the NBC News Investigative Unit.

Originally posted here:
Here are some of the existing drugs that may be repurposed to treat coronavirus - NBCNews.com

Read More...

Visiongain Report: Global Rheumatoid Arthritis Drugs Market Estimated to Grow at a CAGR of 0.6% in the Second Half of the Forecast Period – P&T…

Thursday, March 19th, 2020

- Global Rheumatoid Arthritis Drugs Market Forecast 2020-2030

- Biologics, Non-Biologics, NSAIDs, sDMARDs and Others

LONDON, March 18, 2020 /PRNewswire/ -- The global Rheumatoid Arthritis market is estimated to have reached $58bn in 2018 and is expected to grow at a CAGR of 0.6% in the second half of the forecast period. In 2018, the biologics submarket held 85% of the global Rheumatoid Arthritis market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new236-page reportyou will receive180 tables and 121 figures all unavailable elsewhere.

The 236-page Visiongain report provides clear detailed insight into the rheumatoid arthritis market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.comor refer to our website: https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2020-2030/#download_sampe_div

Report Scope

Global Rheumatoid Arthritis Marketforecast from 2020-2030

Revenue forecasts for theRheumatoid Arthritis Market by Drug Classfrom 2020-2030: Biologics Non-Biologics: NSAIDs, sDMARDs, Others

Revenue forecasts for theRheumatoid Arthritis Market by Drugsfrom 2020-2030: Humira Enbrel Remicade Rituxan/MabThera Simponi/Simponi Aria Orencia Actemra/Roactemra Cimzia Celebrex Xeljanz Arcoxia Others

Revenue forecasts for theRheumatoid Arthritis Market by Regionfrom 2020-2029: North America: U.S., Canada Europe: Germany, UK, France, Italy, Spain, Russia, Rest of Europe Asia-Pacific: Japan, China, India, Rest of Asia-Pacific Latin America: Brazil, Mexico, Rest of Latin America Middle East & Africa: Saudi Arabia, South Africa, Rest of MEA

Profiles of these selected leading companies: AbbVie Amgen, Inc. Bristol-Myers Squibb Eli Lilly and Company F. Hoffmann-La Roche Ltd Johnson & Johnson Merck & Co. Novartis AG Pfizer Sanofi S.A. UCB

Analysis of the Drivers, Restraints, Opportunities and Threats of the global rheumatoid arthritis drugs market

The report also includes SWOT Analysis of the Global rheumatoid arthritis drugs market

Key questions answered by this report: How is the Rheumatoid Arthritis drugs market evolving? What is driving and restraining the Rheumatoid Arthritis drugs market? What are the market shares of each segment of the overall Rheumatoid Arthritis drugs market in 2018? How will each Rheumatoid Arthritis drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030? How will the market shares for each Rheumatoid Arthritis drugs submarket develop from 2020 to 2030? Which individual therapies will prevail and how will these shifts be responded to? What will be the main driver for the overall market from 2020 to 2030? How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030? Who are the leading players and what are their prospects over the forecast period? How will the industry evolve during the period between 2020 and 2030?

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.comor refer to our website: https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2020-2030/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.comto discuss any customized research needs you may have.

Companies covered in the report include:

4SCAbbVieAbivaxAblynx NV SanofiAdheron Therapeutics, Inc.Akari Therapeutics PlcAlder BiopharmaceuticalsAmgenAnacorAraim Pharmaceuticals, Inc.argenxArtax Biopharma, Inc.Astellas Pharma IncBaxalta IncorporatedBiocon Ltd.BiogenBioxpress TherapeuticsBoehringer IngelheimBristol-Myers SquibbCadila HealthcareCambridge Biotechnology Ltd.CASI PharmaceuticalsCatabasis PharmaceuticalsCelltex Therapeutics Corp.Celltrion, Inc.ChemoCentryxChugai Pharmaceutical Co., Ltd.Coherus BioSciences IncCovagen AGCyclacel PharmaceuticalsCyxone ABDaiichi SankyoDePuy SynthesDr Reddy's LaboratoriesEli LillyEpirus BiopharmaceuticalsFive Prime TherapeuticsFresenius KabiFujifilm CorporationGalapagos NVGaldermaGenentechGerresheimerGiaconda Ltd.Gilead Sciences, Inc.GlaxoSmithKline plcGlenmark Pharmaceuticals Ltd.Hanmi Pharmaceutical Co Ltd.HospiraImmunomedicsIncyte CorporationInnate Pharma - IPO PendingIntasItalfarmaco SpAIzana Bioscience Ltd.Janssen BiologicsJohnson & JohnsonKadmon HoldingsKyowa Hakko Kirin Co LtdLycera CorporationMedigeneMerck & Co.MesoblastMitsubishi Tanabe PharmaMomentaMorphosysMycenax BiotechMylan NVNeovacs SANeuBase Therapeutics, Inc.Novo NordiskOnyx Pharmaceuticals, Inc.OphthaliX, Inc. Can-Fite BioPharma LtdOutlook Therapeutics, Inc.PadlockPfizerPhilogen SpAPrincipia Biopharma, Inc.Protalex, Inc.Protalix BioTherapeuticsRa Pharmaceuticals Inc.Regeneron Pharmaceuticals, Inc.RocheSamsung BioepisSanofiShanghai CP Guojian PharmaceuticalsSpirig Pharma A.G.Takeda PharmaceuticalsTheravance Biopharma, Inc.TiGenix NV Takeda PharmaceuticalUCBVitaeris Inc,XencorXOMAZynerba Pharmaceuticals

Other Organisations Mentioned in the ReportAmerican College of RheumatologyNurses HealthWHONational Rheumatoid Arthritis SocietyUnited NationsUS Patent OfficeEuropean CommissionU.S. Food and Drug Administration (FDA)Committee for Medicinal Products for Human Use (CHMP)Centers for Disease Control and Prevention (CDC)World BankArthritis FoundationCanadian Arthritis SocietyWorld Arthritis DayNational Rheumatoid Arthritis SocietyServizio Sanitario Nazionale (SSN)Ministry of HealthNational Institute on AgingNational Center for Biotechnology InformationUnified Health SystemANVISA (Agncia Nacional de Vigilncia Sanitria)African League of Associations in RheumatologyInternational League of Associations for RheumatologyGovernment of Abu DhabiJohns HopkinsBumrungradCleveland ClinicVamedEmirates Arthritis FoundationNational Treasury of Republic of South AfricaEuropean Medicines AgencyNational Institute for Health Research (NIHR)National Institute for Health and Care Excellence (NICE)Institute for Quality and Efficiency in HealthcareInstitut fr Qualitt und Wirtschaftlichkeit im Gesundheitswesen IQWiG

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Global Bioreactors Market 2020-2030

Next-Generation Biologics Market Forecast to 2029

Global Biosimilars and Follow-On Biologics Market 2019-2029

Pharma Wholesale and Distribution Market Forecasts 2020-2030

Translational Regenerative Medicine Market Forecast 2020-2030

Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

Read more:
Visiongain Report: Global Rheumatoid Arthritis Drugs Market Estimated to Grow at a CAGR of 0.6% in the Second Half of the Forecast Period - P&T...

Read More...

DReSS Linked to High Fatality Lung Disease in Juvenile Idiopathic Arthritis – Monthly Prescribing Reference

Thursday, March 19th, 2020

After careful consideration, the American Academy of Allergy, Asthma & Immunology canceled its annual meeting that was to take place in Philadelphia, Pennsylvania from March 13 to 16, because of concerns regarding the coronavirus disease 2019 (COVID-19) outbreak. Although the live events will not proceed as planned, our readers can still find coverage of research that was scheduled to be presented at the meeting.

Drug reaction with eosinophilia and systemic symptoms (DReSS) with exposure to interleukin (IL)-1 or IL-6 inhibition may be linked to high fatality lung disease and poor outcomes in systemic juvenile idiopathic arthritis (sJIA), according to research intended to be presented at the American Academy of Allergy Asthma and Immunology (AAAAI) annual meeting.

Using REDCap databases, researchers collected retrospective observational data for 63 patients with sJIA with lung disease who were diagnosed by 55 physicians from 39 institutions. Researchers evaluated DReSS in patients by using the validated RegiSCAR scoring system.

Of the 63 patients with sJIA and lung disease, 48 had unusual high fatality lung disease associated with IL-1 or IL-6 inhibition. A total of 15 patients were scored with definite DReSS (score, >5/9) and 8 with probable DReSS (score, 4-5/9). At the time of eosinophilia diagnosis, all 23 patients had been exposed to 1 medications, including anakinra, tocilizumab, canakinumab, and rilonacept. Despite concurrent steroid treatment (0-2 mg/kg/d), median peak peripheral eosinophil count was 1725 (range, 754-13,156; 6%-45% of white blood cells) in patients with definite DReSS; facial rash with angioedema was reported in 12 patients.

Among patients in the definite DReSS group, 8 patients stopped the suspected medication, of whom 6 survived (median survival since lung disease diagnosis, 4.7 years) and 2 died after restarting the medication. The remaining 7 patients who continued the medication died.

Overall, the researchers concluded that, DReSS with lung involvement is a high fatality illness. Unrecognized DReSS with exposure to anti-IL-1/IL-6 may account for lung disease and poor outcome in some sJIA cases.

Reference

Saper V, Mellins E, Kwong B. Drug reaction and high fatality lung disease in systemic onset juvenile idiopathic arthritis (sJIA). J Allergy Clin Immunol. 2020;145(Suppl 2):AB95.

This article originally appeared on Pulmonology Advisor

Read more:
DReSS Linked to High Fatality Lung Disease in Juvenile Idiopathic Arthritis - Monthly Prescribing Reference

Read More...

They’re Back in the Game – HealthCentral.com

Thursday, March 19th, 2020

As anyone who lives with a chronic illness knows, the plans you have for your life cant always be counted on. Sometimes, theres no amount of trying that will ever be enough to meet those hoped-for goals. And sometimes, you have to let your body lead the way to a future your never imagined.

In 2010, Kirsten Schultz, now 31, was working on a masters degree in Islamic studies and Arabic language at the University of Wisconsin in Madison. Their ultimate goal? To make a difference in the world by working as a diplomat. (Schultz uses the pronoun they). And theyd gotten this far by sheer determination. Schultz had literally clawed their way through college, fighting symptoms of rheumatoid arthritis every step of the way. Not only did they work multiple jobs, Schultz battled frequent illnesses and disease flares. But by the time they began work on their graduate degree, new medication had gotten Schultzs symptoms mostly under controluntil they werent.

Like most treatments for RA, Schultzs medication works to suppress the overactive immune response thats causing the joint pain and inflammation; as a result, patients are often more vulnerable to infections. And during grad school, Schultz seemed to get anything and everything that was floating around campus.

Professors docked points when they missed classes, which happened frequently. Some days Schultz just couldnt get there. Daily Arabic classes really required near perfect attendance and missing even one day a week meant a lot of makeup work, Schultz explains. On weeks where I missed more than one day, I was honestly just a body in a classroom. Physically and emotionally, I felt like I was drowning.

Battling these illnesses on top of the fatigue, pain, and brain fog that was just part of living with their arthritis eventually made it almost impossible for Schultz to manage their course load. Something was going to have to change. After 18 months of struggling, they decided to withdraw from school in 2012.

Everything I had worked for for so long, I couldnt do anymore, Schultz says. Dropping out of school was one of the hardest things Ive ever done. As someone who loves learning, being unable to continue studying a subject I was incredibly passionate about was devastating. To admit I was sick enough to have to stop school alone was incredibly hard to do. Many people with disabilities struggle with coming to terms with limitations that we face, and this was that moment for me.

And over the next year, Schultzs depression grew deeper. A close friend had died. Their dream of having a career in world diplomacy was over. And their body just kept letting them down. But somehow, from somewhere deep inside, there was a little voice that told them not to give up.

One of the first things Schultz did was put their energy into their blog. It was an outlet for me to process what I was dealing withand help others by talking about it, they explain. Researching topics to write led me to writing for other organizations and to some really cool opportunities such as attending conferences using a press pass.

They also started volunteering, just a few hours a month at first, with the Arthritis Foundations Arthritis Ambassador Group as way to help enact change, and soon was invited to speak at events.

After that, my volunteering picked up, Schultz says. I was working with not only the AF but also with the International Autoimmune Arthritis Movement, National Arthritis Research Foundation, and other arthritis-based orgs. Doing all this helped me truly feel like I was giving back.

By 2014, Schultz felt like their life was starting to pick back up. They got married, continued with their advocacy work, and even started a new job at the local medical school, which opened their eyes to whole other side of health care, especially the quality-improvement process. Seeing what happens on the healthcare-system side and combining that with what I've seen from the patient side pushed me to want to help improve the overall system, they say.

Schultz had found a new path, perhaps the one they were always meant to follow. In 2015, they began a new masters degree in health administration with a focus on patient advocacy. But this time, they enrolled in an online program to better protect their health.

"Going to school online was such a better fit for me, Schultz says. I could work on classwork, group projects, and attend virtual classes without having to worry about germs, parking, or even wearing pants! Once I got back into the grove of attending classes, I felt amazing. The excitement that I have always felt about learning came back and, for the first time in three years, it felt like my brain fog had lifted."

Finally, in 2017, Schultz earned their degree. "To go from being unable to finish my previous attempt to finishing this one that meant so much more to me personally because of the subject matterits something that I can't describe in words very well. Just knowing I was smart enough and could accomplish this was well worth the degree."

But even with this huge accomplishment to launch them into their next chapter, Schultzs health pulled them back once again. On top of their RA symptoms, Schultz was diagnosed with two additional conditions, hypermobility syndrome, which had been causing increased joint pain, and mast-cell activation syndrome (MCAS), an immunological condition that can cause anaphylaxis and near-anaphylaxis.

The hypermobility was something that I have always had, but it was never diagnosed, Schultz explains. The MCAS makes them extremely sensitive to certain common chemicals. I cant walk down the detergent aisle in the supermarket because I cant take the fumes. Just breathing in certain products triggers symptoms of mild anaphylaxis for me.

For a while, Schultz opted to work part-time and continue advocating for other people via their websites. Along with their blog, they founded Chronic Sex.org, an online forum for people who have disabilities to discuss and learn about sexual issues. Schultz got the idea after attending an Arthritis Introspective conference at which they realized that a lot of the attendees, old and young alike, didnt really know much about basic sexual education. I realized how many people with disabilities get excluded from sex ed, and I wanted to start a forum to help change that, Schultz recalled.

Schultz has traveled internationally to speak at conferences, launched a podcast, and is in the process of developing a Chronic Sex research arm, called ORCHIDS: The Organization for Research on CHronic Illness, Disability, and Sexuality. Then last year, Schultz got their dream job working for a nonprofit dedicated to advocating for the rights of people with disabilities.

"I feel very honored to [help] create positive change. While working in health and sexuality are completely different than what I expected to be doing when I finished my undergraduate degree, I've been able to find ways to still do things I enjoy like research and giving talks, Schultz says. Being able to take on projects and get grants has been wonderfully emotionally. These were things I didn't think I'd be able to do in 2012, and I feel very lucky. My health is still an issue, but thankfully it gets to be on the backburner more days than notand that's pretty great."

Also pretty great? Schultzs journey with arthritis helped them discover another passion. Theyd been in physical therapy when theyd discovered a local LGBTQ hockey team. Throughout their work with Chronic Sex, Schultz had learned a lot about who they were, too, including that they were non-binary and pansexual. Their marriage had ended partly as a result.

"I had been so sick all the time and always had to figure out how to manage my health issues, Schultz explains. I never really had time to have a social life and, with the divorce, I needed to fix that. So Schultz ask their P.T. if itd be safe to play, and the therapist was 110% supportive, Schultz recalls.

The first day of hockey was comical, and I was very sore afterwards, Schultz says. I mean, here I am living with arthritis and my body doesnt move correctly anyway, and there I am standing on skates on the ice. But I loved it and, even though I only skated for five minutes of the entire hour, I couldnt wait to go back.

Schultz plays goalie, a position that taught its own set of lessons. They say: As goalie, I have learned that one night you can stop every puck and another night, you can stop none. There is a lot of luck involved. I think knowing this has made it a lot easier for me to let go and not feel like I have to be in control all the time.

The team has also been a source of new friendships. The amount of support that I have gotten has been incredible, Schultz says. Having a really large group of people to lean on for support has been completely life-changing.

Schultz always likes to have a plan in place, and theyre feeling good as they look forward to the years ahead: I am still going with the notion of not putting a lot of expectations on myself and on what my future looks like, they say. But I've started to work with my body more often than against it. Funny enough, part of teaching other people about self-love and self-esteem has meant having to learn what I teach! That alone has been worth this entire journey. Instead of getting upset at my body, I give myself space and graceto mess up, rest, and try again tomorrow."

See the rest here:
They're Back in the Game - HealthCentral.com

Read More...

Arthritis Drug Being Tried on Italian Coronavirus Patients – The St. Kitts-Nevis Observer

Thursday, March 19th, 2020

The situation in Italy is dire when it comes to COVID-19 currently with more than 1,000 deaths. Authorities and science are doing the impossible to make progress in combating this virus. Tocilizumab is a drug that treats moderate to severe rheumatoid arthritis. It can also treat polyarticular juvenile idiopathic arthritis (PJIA) and systemic juvenile idiopathic arthritis (SJIA).

Now its being tried on COVID-19 and with some encouraging results.

A Chinese -Italian Team in Napes, Italy has been experimenting with this drug to fight Covid-19. This news was spread in the Italian press and from the sources of Italian secure communications: RAI-TV

A collaboration between the Colli Hospital, the Cancer Institute of Naples and Chinese doctors, it was verified that Tocilizumab can give positive results in the care of people infected with Coronavirus.

Two patients from Naples immediately responded

The drug was administered to two patients hospitalized at Cotugno Hospital (in Naples), suffering from severe Covid-19 pneumonia last Saturday. 24 hours after the infusion, encouraging improvements were highlighted, especially in one of the two patients, who arrived at the hospital as a particularly critical case. This was reported by the Neapolitan hospital of the Hills.

The same drug has been used in China in 21 patients and now for the first time has been administered in Italy in Coronavirus patience.Based on this experiment it is currently evaluated if treating other critically ill patients is recommended.

The International team

The result was made possible thanks to a great team effort mentioning: the Oncology of the Azienda dei Colli by Vincenzo Montesarchio, the Oncological Immunotherapy and Innovative Therapies of Pascale by Paolo Ascierto together with the virologist Franco Buonaguro, and some Chinese doctors, including Wei Haiming Ming from the First Affiliated Hospital of University of Science and Technology of China as well as the team of doctors from Cotugno, composed among others by Rodolfo Punzi, director of the department of infectious diseases and infectious diseases, Roberto Parrella, director of Uoc Diseases respiratory infectives, Fiorentino Fragranza, director of the Uoc Anesthesia resuscitation and intensive care, Vincenzo Sangiovanni, director of the Uoc Systemic infections and immunosuppressed, Nicola Maturo, head of the Infectivology First Aid always by Cotugno and Luigi Atripaldi, director of the Microbiology laboratory and virology.

The Chinese experience

Paolo Ascierto and Vincenzo Montesarchio explained out how 21 patients had been treated. All of them showed a visible improvement already in the first 24-48 hours after treatment. Treatment included a single solution It acted without interfering with the protocol therapeutic use based on antiviral drugs.

The downside:

According to Gunther Franke, a pharmacist in Cologne, Germany this news may be good also for Roche Pharma, the manufacturer of the medicine. 4 injections sell for 1900,00, 12 injections for 5800,00

More here:
Arthritis Drug Being Tried on Italian Coronavirus Patients - The St. Kitts-Nevis Observer

Read More...

Existing drugs may have a key role to play in coronavirus treatment – inews

Thursday, March 19th, 2020

NewsHealthLeading scientists believe 'hyperinflammation' drugs could help with worst cases of the virus

Sunday, 15th March 2020, 6:50 pm

Existing drugs for rheumatoid arthritis and cases of excessive inflammation could be used to treat some of the most severe cases of coronavirus, leading scientists say.

A recent study into coronavirus deaths in China suggested that many of the fatalities were caused by an overactive immune response in the body that was triggered by the virus - rather than by the virus itself.

This suggests that existing drugs designed to suppress these kind of overreactions in the immune system - known as 'hyperinflammation' or cytokine storms - have the potential to significantly reduce casualties from Covid-19.

However, clinical trials are needed to confirm whether these drugs are an effective coronavirus treatment, according to a panel of scientists and clinicians researching the issue.

Screen worst-hit patient

The researchers recommend that all patients who are suffering badly from coronavirus be screened for hyperinflammation with a blood test - and given steroids or other approved drugs if they are found to have it.

Deaths from Covid-19 are rising and there is an urgent need for effective treatment. We recommend identification and treatment of hyperinflammation using existing, approved therapies with proven safety profiles to address the immediate need to reduce the rising mortality, Puja Mehta, of University College London, told i.

Improving awareness of the risk of hyperinflammation and treating patients with immunosuppression therapies is likely to be important in the pandemic, she said.

"Deaths from Covid-19 are rising and there is an urgent need for effective treatment,"

Puja Mehta

Dr Mehta was speaking on behalf of a collaboration of five hyperinflammation experts from universities and hospitals across the UK. They have written an article for The Lancet journal, seen by i, outlining their case.

Immunosuppressants such as the rheumatoid arthritis treatment Actemra, anti-inflammatory 'cortico' steroids and intravenous immunoglobulin blood treatments are used to dampen the immune response and save lives.

Study of Chinese cases

A recent study into 150 cases of Covid-19 cases in China found a link between fatal cases of coronavirus and cytokine storms.

It is recognised that some patients with severe Covid-19 may have hyperinflammation which can be picked up by blood tests.

Where hyperinflammation is shown this is associated with severe coronavirus symptoms and may predict death, Dr Mehta said.

During a cytokine storm, an excessive immune response ravages healthy lung tissue, leading to acute respiratory distress and multi-organ failure. Untreated, cytokine storm syndrome is usually fatal.

Trial of arthritis treatment

Chinese authorities have approved the use of the Actemra rheumatoid arthritis treatment for lung damage arising from coronavirus.

Meanwhile, Chinese researchers have started a trial to assess the safety and effectiveness of using the drug in coronavirus patients with cytokine release syndrome.

Here is the original post:
Existing drugs may have a key role to play in coronavirus treatment - inews

Read More...

Profiles in Creating Possible: Julie Di Paolo is on a Mission to Understand Rheumatoid Arthritis and Other Inflammatory Diseases Press Releases on -…

Thursday, March 19th, 2020

Stories @ Gilead

When Julie Di Paolos father was diagnosed with Crohns disease, an inflammatory condition with limited treatment options, it sparked curiosity and drive that have carried forward into her career at Gilead, where she is Executive Director of Inflammation Biology.

I realized how few medications were being developed to treat the drivers of inflammatory diseases, and how far away the field was from delivering curative therapy, she recalls. That still sticks with me today.

Julie joined Gilead in 2010, as the company was further expanding its work outside of antivirals. While there have been moderate advances in disease understanding and treatment options, significant unmet needs remain for people living with inflammatory conditions. An estimated 38 million people around the world live with inflammatory diseases and two-thirds of patients do not achieve the current treatment goal of disease remission. According to Julie, progress is being made but much more is still needed.

Rheumatoid arthritis is an example of an inflammatory disease where a lot of the underlying pathways arent well understood, Julie explains. When someone is diagnosed, its not clear whether a particular therapy is going to work for that person. Its essentially a process of elimination until the physician and patient find the right option. Really pairing the right therapy with the right individual is the aspirational place that we want to go. We want to get a much deeper response, and bring relief to more people.

Julie and her team research a broad range of inflammatory diseases, with particular focus on studying small molecules that have the potential to inhibit the Janus kinase (JAK) family of four proteins, some of which are highly active in inflammation. Inhibiting these proteins, particularly JAK-1, has the potential to reduce inflammation, associated symptoms and disease progression.

While there is still much work to be done to fully understand the complex pathways that contribute to inflammatory diseases, Julie says headway is being made.

It starts with incrementally making progress toward understanding a disease and seeing how you can chip away at getting better responses to treatment, Julie says. The ultimate goal is to eventually get to a place where the disease is so well-maintained that it no longer impacts a persons quality of life.

Julie and her team are approaching inflammation from all sides, in what she calls an ABC treatment paradigm. The objective is toArrestthe disease, or stop it where it is and prevent it from getting worse. From there, the next step is toBalancethe condition by creating a tolerogenic environment and reducing the source of inflammation. Eventually, the team believes it will be necessary toCombinetreatments to achieve long-term control of many inflammatory diseases.

Recent progress has enabled Gilead to submit an investigational JAK-1 inhibitor for regulatory review in the United States, Europe and Japan. Addressing the existing gaps in the current standards of care also require partnerships, says Julie, pointing to Gileads 10-year global research and development collaboration with Galapagos. Scientists from the two companies are working together closely to discover and develop potential new therapies.

In science, its all about finding the truth, Julie says. These types of partnerships help create new possibilities for people living with inflammatory diseases. They allow us to bring all of the best ideas together and work collaboratively to advance those that make the most sense.

Originally posted here:
Profiles in Creating Possible: Julie Di Paolo is on a Mission to Understand Rheumatoid Arthritis and Other Inflammatory Diseases Press Releases on -...

Read More...

Combating arthritis: How to deal with this crippling disease – Free Press Journal

Thursday, March 19th, 2020

X-rays are generally a good guide to whats wrong with your hip, however it may be difficult to get complete assessment of X-rays especially in early disease, where the changes in the bony architecture may not be easily visible. Magnetic Resonance Imaging (MRI scans) are a great tool to assess the disease process and formulate plan of treatment.

Treatment plan

Once the complete assessment is done, the treatment plan is outlined based on the problems faced and the amount of pain and disability the patient has due to arthritis.

In early disease, the treatment starts with changes in the lifestyle and anti inflammatory medicines. Patient should avoid sitting on the floor and squatting. They are motivated to maintain their muscle strength and hydrotherapy and swimming are a good way to maintain movement and stamina without further damaging the already diseased joint.

A good physiotherapy protocol is formed to give them better quality of life in future. In cases of proven Rheumatoid Arthritis and Ankylosing Spondylitis, a Rheumatology specialist opinion is helpful to give them course of Disease Modifying Medicines. They help in control of the arthritis and delay the surgery to a certain extent.

When there is damage to the blood supply, medicines to reduce the blood coagulation may be effective. The aim of the non operative management is to maintain the hip strength and flexibility, and even after taking all the precautions, the disease may progress gradually to a level where a surgical intervention is needed.

When the arthritis gets worse, the patient may have to undergo some surgical intervention to be able to mobilise and lead pain free life. Although difference types of surgeries are available, you may have to head to total knee replacement in severe disease.

The results of the procedure are very predictive and patients lead nearly normal and productive life after undergoing the surgery. They get pain free range and mobility and good quality of life after surgery.

The prosthesis and bearing surfaces have also evolved over decades and the invent of Ceramic and Oxynium heads have given us hope for increased survival of the replaced joint for longer term.

And the newer cement-less designs have better integration into the bone and enable to get fixation without cement, thereby nullifying cement related problems.

If you have hip problems in early age, do visit your orthopaedic surgeon to find a right solution. Timely treatment could help delay surgery and maintain good quality active life.

Go here to read the rest:
Combating arthritis: How to deal with this crippling disease - Free Press Journal

Read More...

Global Psoriatic Arthritis Therapeutics Market To Witness Towering Growth And Surpass USD 16.71 Billion By 2025 – Bandera County Courier

Thursday, March 19th, 2020

Zion Market Researchalways aims at offering their clients an in-depth analysis and the best research material of the various market. This new report on theGlobal Psoriatic Arthritis Therapeutics Market Is Expected To Reach Around USD 16.71 Billion By 2025is committed fulfilling the requirements of the clients by giving them thorough insights into the market. The Psoriatic Arthritis Therapeutics Market report, titled Psoriatic Arthritis Therapeutics Market, is expansive research reliant on Psoriatic Arthritis Therapeutics Market, which inspects the raised structure of the present Psoriatic Arthritis Therapeutics Market all around the globe. Arranged by the adequate methodical framework, for instance, SWOT examination, the Psoriatic Arthritis Therapeutics Market report exhibits a total evaluation of the significant players of thePsoriatic Arthritis Therapeutics Market. The estimates for CAGR (Compound Annual Growth Rate) is calculated by the Psoriatic Arthritis Therapeutics Market report in terms of extent for the specific time length. This will similarly help the customer with comprehension and settle on a correct choice depends on a normal chart.

Request Free Sample Report of Psoriatic Arthritis Therapeutics Market Report @https://www.zionmarketresearch.com/sample/psoriatic-arthritis-therapeutics-market

Some of the Major Psoriatic Arthritis Therapeutics Market Players Are:

AbbVie, Amgen, Celgene Corporation, Janssen Biotech, UCB, Pfizer, Biogen, Novartis AG, Eli Lilly and Company

This report similarly comprises of the bifurcation of the Psoriatic Arthritis Therapeutics Market by the type of product, its end-users, applications, and others . Moreover, Psoriatic Arthritis Therapeutics Market report gives an arrangement regard to the Psoriatic Arthritis Therapeutics Markets components, by pinpointing a couple of edges including limitations, regard chain, utilization foundation, and client affirmation. The Psoriatic Arthritis Therapeutics Market report is assembled of direct experiences isolated from the emotional and quantitative assessment by Psoriatic Arthritis Therapeutics Market agents, competition between them, strategies, Psoriatic Arthritis Therapeutics Marketing, production, research, and development. Moreover, Psoriatic Arthritis Therapeutics Market report addresses a methodical appraisal of macroeconomic markers, parent Psoriatic Arthritis Therapeutics Market inclines and developed components together with the Psoriatic Arthritis Therapeutics Market.

Also, the emotional effect is charted by the examination of different provincial regions[Latin America, North America, Asia Pacific, Middle & East Africa, and Europe]together with segments. The Psoriatic Arthritis Therapeutics Market globally is the cornerstone of the development angles and prospects, as the improvement of a specific arrangement needs numerous mechanically upheld hypothesis, thoughts, and systems. The Psoriatic Arthritis Therapeutics Market report contains in general successful system, confinements, and top to bottom illumination of the past information alongside the present and future needs that might concern the development. The Psoriatic Arthritis Therapeutics Market report affirms an exhaustive synopsis of the present development, variables, enumerating, and creation. The Psoriatic Arthritis Therapeutics Market report additionally conveys a total dynamic of the money related good and bad times concerning request rate and satisfaction proportions.

Download Free PDF Report Brochure @https://www.zionmarketresearch.com/requestbrochure/psoriatic-arthritis-therapeutics-market

Promising Regions & Countries Mentioned In The Psoriatic Arthritis Therapeutics Market Report:

Following 15 Chapters represents the Psoriatic Arthritis Therapeutics Market globally:

At last, the global Psoriatic Arthritis Therapeutics Market gives the readers a complete view of the market during the forecast period from 2020-2026 which will assist them in making right business choices that will lead to development the development of their company.

Inquire more about this report @https://www.zionmarketresearch.com/inquiry/psoriatic-arthritis-therapeutics-market

Worldwide Psoriatic Arthritis Therapeutics Market Report Provides Comprehensive Analysis of:

Questions covered in Worldwide Psoriatic Arthritis Therapeutics Market Industry research report:

What are current global Psoriatic Arthritis Therapeutics Market market tendencies, obstructions, and challenges faced by the key competitors of Psoriatic Arthritis Therapeutics Market market?

What are major outcomes and consequences of the five strengths study of Psoriatic Arthritis Therapeutics Market industry?

What will be the Psoriatic Arthritis Therapeutics Market market capacity and growth estimation forecast up to 2026?

Who are the major players in the world Psoriatic Arthritis Therapeutics Market market and what ways they follow to increase overall revenue?

What are the durabilities and defects of the Psoriatic Arthritis Therapeutics Market industry?

Request Report TOC (Table of Contents) @https://www.zionmarketresearch.com/toc/psoriatic-arthritis-therapeutics-market

Reasons to buy:

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Follow this link:
Global Psoriatic Arthritis Therapeutics Market To Witness Towering Growth And Surpass USD 16.71 Billion By 2025 - Bandera County Courier

Read More...

Gerth: Coronavirus outbreak will take its toll, but we’ll get through it as we always have – Courier Journal

Thursday, March 19th, 2020

With a viral outbreak prompting the WHO to declare a global health emergency, let's take a look at what a coronavirus is. Louisville Courier Journal

There are points in our history that we'll always remember.

For some, it was the Kennedy assassinations. Both of them. Or when MLK was gunned down. For others, the Nixon resignation. Or the Challenger explosion, or the attack on the World Trade Center.

We can now add the coronavirus to the list of events that have changed our outlooks, inexorably altered the path of our country and forced us to take stock in our own lives.

"I'm shaking," said Frank Foster, ashe held court Thursday at the big round table in the middle of Franco's Restaurant, which he opened13 years ago. He admitted feeling helpless if the pandemic spikes here as it did in Wuhan, China, and Milan.

"I wouldn't know what to do," the 78-year-oldsaid."I've never been through anything like this before."

There's a good reason he was shaking. A lot of us were.

That day Thursday was the most memorable awful day of a memorable awful week.The news was filled with dire warnings from our elected officials.

Frank Foster, right, the owner of Franco's, said he is "shaking" because of the coronavirus.(Photo: Joseph Gerth)

[Want to know all the Kentucky-related coronavirus news? Download our app.]

That day saw the Dow Jonesplummet2,353 points the worst drop since the stock market crash of 1987. It saw schools throughout the state begin to close as we try to protect our children from catching the virus and bringing it home to sicken us and theirgrandparents.

That horrible day saw more and more things like plays and concerts events where we gather to have fun and celebrate life put on hold.

Considered impossible just a couple of days earlier, the Kentucky High School Athletic Association called off the Sweet Sixteen basketball tournaments.

And perhaps in the most stunning move of all for us, it saw the NCAA cancel March Madness, do away with spring sports altogether, and it saw most major professional sports suspend or delay their seasons.

By Saturday, Kentucky had at least 16 positive tests for the coronavirus.

Gov. Andy Beshear has consistently warned us that there will be more.

While we haven'thad any of the deaths here like in Washington and California and a few other states, it'shard to imagine the coronavirus hasn't stolen from each of us something we love whether it's learning or sports or our ability to retire. Or if it's just our peace of mind.

Mark Rucker, a 50-year-old real estate lawyer in Lexington, is worried.

About 80%of the people who get COVID-19 have mild or no symptoms, according to the World Health Organization. But older adults and people with serious chronic medical conditions including heart disease, kidney disease, diabetes and lung disease are at higher risk, according to the Centers for Disease Control and Prevention.

Kentucky coronavirus live updates: Get the latest information here

He's in the 20% none of us wants to be in.

Rucker has kidney disease andrheumatoid arthritis, which requires him to take a steroid that suppresses his immune system.

On Monday, the news came that the first positive test for the coronavirus had been reported in Lexington. This had him especially on edge.

So on Tuesday morning, he got up and went to his kidney doctor for a previously scheduled appointment.

"I wore an N95-rated mask to my appointment for the first time ever," he said. "I did feel slightly awkward but again, being around other immune-compromised individuals just really made me think 'better safe than sorry.'"

It's scary for many people.

State officials are telling people to stay away from crowds. They're telling us to keep 6 feet between us and others. It's up to that distance that a cough or a sneeze will pose a risk to others. If you're over age 60 or in poor health, you're told not to get on a plane, and for gosh sakes, everyone stay away from cruise ships.

Employers are telling many of us not to go to the office where we can spread the disease. I'll be filing columnsfrom my recliner most days for the next few weeks; my wife will be on her computer across the room; and my daughter will probably be holed up in her bedroom.

Apple Stores have shut down. Others will likely follow.

Some people have gone overboard. Fear has caused them to hoard groceries and toilet paper.

Coronavirus tracker: How manycases are in Kentucky? Where are they?

Autoplay

Show Thumbnails

Show Captions

This will go on for weeks, if not months, as a vaccine isn't expected to be ready until later this year.

The dregs of society are trying to profiteer. One man in Tennessee had amassed 17,700 bottles of hand sanitizer and was selling them for many times their original value before Amazon and eBay stopped price gouging on their platforms, The New York Times reported.

Heshould choke on a bottle of Purell.

Hoarding begets hoarding. Others started buying up everything in groceries. Pasta. Bread. Rice. Toilet paper. Hand soap. Lysol Wipes. Even fresh fruit, which one would think would rot before hoarders eat it, was wiped out in grocery stores.

At Kroger on Friday, I looked around at the empty shelves and felt I knew what it was like to live in the old Soviet Union.

Delta Air Lines announced Friday that it was grounding 40% of its flights as people avoidcommercial carriers.

For someone like Mike Goetz, deciding whether to travel or to be in large crowds could be a life or death decision. He was diagnosed with leukemia about a year ago.

Because of the virus, Goetz and his wife have decided not to fly to Palm Springs, California, this month for a family vacation they had been planning.

My hematologist said, I dont want you on a plane right now. I dont think its prudent,'" Goetz said.

Now, the family is struggling about whether to cancel his daughters March 28 wedding in Nashville, Tennessee.

"Ive had quite a few older family members inform me in the last few days that they wouldnt be coming, he said. Ive never seen such a fluid situation and things changing so quickly in my life.

Read more: Louisville stores flooded by shoppers panicked over coronavirus

Steve Hankins, of Shepherdsville, isn't going to be traveling either.

He was in Saugus, Massachusetts, on business last weekend when he fell ill.

A cough. Shortness of breath. Fever.

He awoke in his hotel room last Sunday morning and drove his rental car to Massachusetts General Hospital and asked a security guard outside where he could find the emergency room.

"STAND RIGHT HERE!" was the order.

Within minutes, someone from the ER gave him a mask and escorted into an isolation room, where doctors began working to figure out what was going on. They determined he had chronic obstructive pulmonary disorder and a bad case of the flu and admitted him to the hospital.

Back in Shepherdsville, his wife was frantic.

Also: As coronavirus fears spread, these small businesses stand to lose big

Why wasn't Hankins, who travels by commercial plane several times a month and passes through airports often,tested for the coronavirus?

The fact is, there just aren't enough tests to go around. People who should be tested aren't being tested.

Only about 150 people in Kentucky have been testedbecause the federal government was slow to react to the burgeoning crises. Because of that, hundreds, or even thousands, of people may be unwittingly spreading the virus in Kentucky.

The virus has interfered with even the simple things in life.

Churches have canceled services.

People are not allowed to visit family in nursing homes unless their loved ones are near death. The rules, necessary to keep the virus away from those most vulnerable to it, are certainly increasing the loneliness and isolation that is already a problem the elderly face.

Some restaurants are empty.

On Friday, Hooked on Frankfort, a fish restaurant within 1.8 miles of five Catholic churches, had only about 15 people eating there at 12:30 p.m. On a Friday. During Lent.

College and university closures were affecting high school students who were planning trips to campuses across the country.

Elise Williamson, a 17-year-old senior at duPont Manual High School,said she learned at about 11 a.m. Tuesday her visit to Yale next month wouldn't happen. She was scheduled to go to New Haven, Connecticut, to learn about financial assistance available to her and then to attend Bulldog Days a three-day orientation program for admitted students.

They were canceling because of the coronavirus, just because of how many students would be coming there, not just from across the country but from around the world, she said.

Williamson said shes disappointed because she thought the orientation programwould have eased her transition to college life, but she said shes in a better position than many students because she was able to visit campus last summer.

Elise Williamson is a senior at Manual High School. She'll be attending Yale University in the fall and had planned an upcoming visit to the school, but it was canceled due to coronavirus precautions.(Photo: Pat McDonogh, Courier Journal)

Dive deep: With coronavirus kits limited, Kentucky is testing only the sickest patients

Law schools at Harvard and University of California, Berkeley, havesaid they aren't sending students to a program at the Appalachian Research & Defense Fund, AppalReD, that helps poor people with their legal troubles and provides an important learning experience for the future lawyers.

On Saturday morning, students at Bellarmine University packed up their belongings and loaded them into cars ordered by the school to vacate the dormitories this weekend.

Wiley Carr III needed only three bags to move out of his dorm room at Bellarmine University: One had his laptop and other class materials. One had some personal hygiene products. The third carried his trumpet.

I understand the safety precautions, Carr,23,said. But this impacts so many students.

Wiley Carr III carried a few belongings after checking out of his dorm on the campus of Bellarmine University on Saturday.(Photo: Sam Upshaw Jr./Courier Journal)

Beshear, who's shown a steady hand warning of the dangers of the virus, has been careful to say at each press conference he's held that "we will get through this."

It's no doubt we will. But it will take its toll.

But we will be forever changed.

We'll think twice about shaking hands for a long time. We'll worry about the next new disease that comes along. And we'll worry if our government will be able to deal with it if it does.

But, as Beshear says, we will get through this.

Information for this column was also gathered by Jonathan Bullington.Joseph Gerthcan be reached at 502-582-4702 or by email atjgerth@courierjournal.com. Support strong local journalism by subscribing today:courier-journal.com/josephg.

Read or Share this story: https://www.courier-journal.com/story/news/local/joseph-gerth/2020/03/14/gerth-covid-19-take-toll-but-well-get-through/5009893002/

Read more:
Gerth: Coronavirus outbreak will take its toll, but we'll get through it as we always have - Courier Journal

Read More...

Page 36«..1020..35363738..5060..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick